Wellness Wars

The underground healthcare system people are building because the one we have failed them.

A person treating themselves with a GLP at home is doing more than losing weight. They’re escaping a costly and miserable future.

A future measured in prescription refills.

Specialist appointments.

Painful joints and worsening bloodwork.

A surgery somewhere down the road.

A complication that becomes another diagnosis.

Eventually, the loss of the ability to live on their own.

None of that is inevitable. Avoiding it is the point of treatment. But here we are. It happens every day.

To the person who’s spent years being told what’s wrong with them, what it will cost, and what their insurance will not cover, the possibility of changing that future feels like more than a medical advance.

It feels like a way out

Peptides have brought that possibility into the kitchen, the refrigerator, and the ordinary routines of daily life. Semaglutide and tirzepatide are the most familiar examples. Their implications extend beyond weight loss into diabetes, cardiovascular risk, kidney disease, liver disease and sleep apnea. Other peptide medicines already help build bone and prevent fractures.

But the science is developing inside a healthcare economy that can make a treatment available on paper and inaccessible in practice. So people are finding another route in the underground healthcare system.

Our present healthcare runs through approved medicines, prescriptions, authorized pharmacies, insurance approvals, and the ability to pay. The emerging underground system runs through online peptide suppliers and communities comparing research, sharing experiences, and looking for access outside those channels.

The beginnings of the underground healthcare system are already visible.

So much so that the split has now reached federal policy in the United States.

In late October, Robert F. Kennedy Jr.'s Department of Health and Human Services published an interim enforcement-discretion policy, released for public comment, covering BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. It sets out circumstances in which HHS does not intend to act against licensed pharmacies and physicians compounding those peptides for individual patients.[11–12]

The rationale matters as much as the list. HHS explicitly recognizes that people are already using research-use-only peptides and argues that access through compounders with ingredient testing, patient-specific prescriptions, and safety reporting offers a more controlled alternative.[11]

This does more than acknowledge the underground. It supports another route to care through licensed compounders, with new rules that favor patients already seeking access outside the approved-product system.

Which peptides are covered?

The six-peptide list covers BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon, subject to the policy's conditions. It does not include retatrutide, and it does not give these six peptides FDA approval.[11]

It also draws a line around peptide blends. The policy requires each compounded product to contain only one active pharmaceutical ingredient from the list. A combined Wolverine peptide blend, commonly marketed as BPC-157 plus TB-500 in one vial, therefore falls outside this policy's enforcement-discretion conditions, even though both ingredients appear individually on the list.[11,13]

“Stack” can also mean using separately supplied products together. That is different from a premixed blend; the policy's single-ingredient condition should not be described as a blanket ruling on every practice called peptide stacking.cccc

The decision opens a defined route for individual peptides. It does not authorize every peptide, combination, or online seller.

The underground system is already substantial enough to influence the rules of the first.

It is incomplete, uneven, and sometimes dangerous. It is also a response to something the established system has failed to provide: a route people believe they can actually use.

For someone priced out of treatment, the alternative is not always a carefully supervised version of the same care. Sometimes the alternative is going without.

That is the context in which Eli Lilly's fight over retatrutide belongs.

Retatrutide remains investigational. Lilly has pursued unauthorized sellers and called on payment processors, online platforms, and shipping companies to help shut their channels down.[10]

Lilly sees a market that should not exist.

The person searching that market may see an option they cannot find anywhere else.

Between those two perspectives sits a much bigger conflict than a patent dispute. Peptides could change how disease is treated, how much care people need, and how much money passes through the businesses surrounding them.

To understand the institutional resistance to affordable alternatives, look beyond the price of the drug.

Look at the future bill.

Here are ten major conditions peptide medicines already treat or have credible human evidence of improving. The figures describe spending on each whole condition; the benefits apply to specific patient groups.

Condition

U.S. annual spending benchmark

What peptide treatment can address

Type 2 diabetes

$143.9 billion

Blood-sugar control and associated disease risks

Ischemic heart disease

$80.7 billion

Major cardiovascular-event risk in eligible patients

Heart failure

$58.6 billion

Worsening heart-failure events in patients with obesity and preserved ejection fraction

Osteoarthritis

$47.5 billion

Knee pain and physical function in patients with obesity

Hypertension

$35.6 billion

Blood-pressure reductions with metabolic treatment

Chronic kidney disease

$14.7 billion

Progression risks in patients with type 2 diabetes and CKD

Obesity

$173 billion

Excess weight and related health risks

Metabolic fatty liver disease

About $103 billion

MASH in a defined patient population

Osteoporotic fractures

$48.8 billion

Fracture risk through bone-building treatments

Obstructive sleep apnea

$12.4 billion

Moderate-to-severe OSA in adults with obesity

The first six categories alone account for $380.96 billion in annual spending in a single study using 2019 dollars and allocating costs across diagnoses.[1] The other four estimates come from separate studies and overlap with that subtotal; they are not added to it.[2–5]

That $381 billion includes hospital, outpatient, emergency, prescription, nursing-facility and home-health spending within the study's coverage.

Those are the businesses around the disease.

A successful treatment can affect more than the prescription it replaces. If it prevents a complication, it may also prevent an emergency visit, an admission, a procedure, or a period in rehabilitation. Avoiding a fracture can mean an older adult stays in their own home.

The human value is obvious.

The financial consequences depend on which side of the transaction you’re on.

A separate study of diagnosed diabetes estimated $306.6 billion in attributable medical spending in 2022. Approximately $96.2 billion went to inpatient hospital care and $9.6 billion to nursing or residential facilities.[6] Those broader figures include complications and are not added to our subtotal.

That is how much larger this is than the diabetes-drug business.

Even a hypothetical 10% reduction in the $381 billion baseline would mean approximately $38 billion a year in avoided existing care. Hold that baseline constant for a decade, and the figure approaches $381 billion.

That is an illustration of scale, not a prediction of peptide healthcare savings. The cost of treatment and monitoring must be deducted, and only part of that spending involves patients these therapies could help. Better knee pain is not proof of regenerated cartilage or an avoided joint replacement.

But the argument does not need those exaggerations.

It already involves conditions that consume hundreds of billions of dollars, and treatments that can change some patients' outcomes.

Now put the two systems back into that picture.

An affordable peptide that helps someone avoid expensive care could reduce both suffering and dependence on the businesses providing that care.

A tightly controlled peptide sold as an expensive continuing treatment could improve health while preserving financial dependence.

The injection happens in the same place. The patient has a very different relationship with whoever supplies it.

That distinction is where the business model becomes the story.

A model organized around exclusive products, restricted competition, and the highest sustainable price can succeed for shareholders while failing people who need treatment.

Calling the product innovative does not resolve that failure. Neither does telling someone it is approved when they cannot afford it.

A breakthrough beyond your reach is still beyond your reach.

The underground market grows in that gap.

People do not have to reject medical science to reject the terms on which it is sold to them. They can want evidence, reliable products, and competent advice while refusing to accept that their income should determine whether they get treatment.

They can also make mistakes. Poor information and unreliable products create real dangers. A seller operating outside the established system does not become trustworthy simply by charging less.

But those dangers are an argument for making reliable care accessible. They are not an answer to the person who has been excluded.

The consequences of exclusion belong in the safety calculation too.

What happens to the person who remains untreated? Whose disease progresses while an appeal is pending? Who sees a viable treatment priced beyond anything they can pay?

When a business preserves a barrier that keeps effective care out of someone's reach, the resulting harm is not justified because the barrier maximizes shareholder value.

That’s why the response to the underground matters so much.

Lilly has sought biologic classification for retatrutide, challenging FDA's refusal to designate it that way.[7] Eligible biologics can receive twelve years of reference-product exclusivity against approval through the abbreviated biosimilar pathway, and biological products fall outside ordinary federal compounding exemptions.[8–9]

These technical distinctions help shape competition and lawful access. Alongside enforcement against unauthorized sellers, they belong in an examination of how many routes patients will have, and on whose terms.

Lilly does not need to oppose the health benefits of peptides to defend a model that excludes people from them.

It can bring a treatment forward and insist that access remain on commercially favorable terms. The people left outside experience the consequences regardless of how the company describes its intentions.

Kennedy's six-peptide policy points toward one response: create a more accountable route for demand that already exists. Lilly's campaign against unauthorized retatrutide sellers illustrates the pressure to close existing routes. The substances and legal circumstances differ, but both developments reveal a system being forced to respond to patients who are already looking outside it.

Meanwhile, the underground keeps growing, driven by unmet need.

Over the next ten years, peptides could address more conditions, prevent more complications, and move more treatment into the home. That makes affordability more consequential with every useful advance.

If the official route remains inaccessible, people will keep looking elsewhere. Enforcement may remove some sellers. It will not remove the need, the knowledge that a treatment exists, or the determination to find it.

A functioning healthcare system would take that determination seriously. It would measure success partly by how much illness people avoid and how little unnecessary care they need.

A business model that treats affordable competition as a threat measures something else. It puts shareholder value above outcomes.

The conflict is already here: scientific possibilities expanding, financial barriers holding, and people building a parallel route between the two.

The person with a peptide in the refrigerator may never think about disease-spending estimates, regulatory classifications, or the economics of a hospital admission.

They may just want to feel better. Keep working. Sleep through the night. Walk without pain. Stay in their own home.

They may want a future that does not require surrendering their savings to their illness.

A healthcare system that cannot make room for that should expect people to find another way.

Sources and calculation notes

Research checked November 4, 2026. Ten major treatment targets, not a ranking by disease cost or a claim that every patient benefits. The $380.96 billion subtotal uses the six mutually allocated categories in source 1, without adding overlapping risk-attribution estimates. It is a disease-spending baseline, not an estimate of avoidable costs or lost profit. The 10% scenario is illustrative.

JAMA/IHME: Tracking US Health Care Spending by Health Condition and County. Published 2025; 2019 spending; partial coverage of national personal healthcare spending. Sum: 143.90 + 80.66 + 58.57 + 47.54 + 35.57 + 14.72 = $380.96 billion.